Week in Review: Beike Biotech In-Licenses Cancer Drug in $200 Million Deal

Shenzhen Beike Biotechnology acquired China rights to a novel cancer immunotherapy developed by Altor BioScience of Florida in a deal potentially worth $200 million;  OrbiMed Advisors closed its second pan-Asia healthcare fund with $325 million in capital; Institute Curie, a major French medical research center and hospital, will partner with a Shenzhen investor to build a $486 million cancer hospital in Shenzhen; Lee's Pharm in-licensed China rights to a second drug from Abiogen Pharma of Italy; Guangzhou Baiyunshan Pharma received CFDA approval to market the first generic version of Viagra in China; Aslan Pharma of Singapore has begun dosing patients in a Taiwan Phase I trial of its lead cancer drug; Mazor Robotics of Israel was granted CFDA approval to market its Renaissance® guidance system for spinal surgeries in China; and ACM Global Central Laboratory, a US-headquartered central lab, opened ACM Shanghai to support clinical trials. More details.... Stock Symbols: (HK: 950) (SHA: 600332; HK: 0874) (TASE: MZOR; NSDQ: MZOR) Share this with colleagues: // //